259 related articles for article (PubMed ID: 36505486)
1. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy.
Zhang YY; Li XW; Li XD; Zhou TT; Chen C; Liu JW; Wang L; Jiang X; Wang L; Liu M; Zhao YG; Li SD
Front Immunol; 2022; 13():1055304. PubMed ID: 36505486
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer.
Chen K; Zhang Y; Li C; Liu Y; Cao Q; Zhang X
Cell Signal; 2024 May; 117():111104. PubMed ID: 38373667
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of cuproptosis-related long noncoding RNA immune infiltration and prediction of prognosis in patients with bladder cancer.
Zhang Y; Li X; Li X; Zhao Y; Zhou T; Jiang X; Wen Y; Meng W; Li S
Front Genet; 2022; 13():990326. PubMed ID: 36186475
[No Abstract] [Full Text] [Related]
4. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
Zhu S; Li H; Fan Y; Tang C
BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
[TBL] [Abstract][Full Text] [Related]
5. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
7. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer.
Cao L; Zhang S; Peng H; Lin Y; Xi Z; Lin W; Guo J; Wu G; Yu F; Zhang H; Ye H
Aging (Albany NY); 2024 Jan; 16(2):1463-1483. PubMed ID: 38226979
[TBL] [Abstract][Full Text] [Related]
9. Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAs.
Deng H; Wei Z; Du J; Shen Z; Zhou C
Eur J Med Res; 2023 Nov; 28(1):548. PubMed ID: 38017579
[TBL] [Abstract][Full Text] [Related]
10. Predicting prognosis, immunotherapy and distinguishing cold and hot tumors in clear cell renal cell carcinoma based on anoikis-related lncRNAs.
Hao C; Li R; Lu Z; He K; Shen J; Wang T; Qiu T
Front Immunol; 2023; 14():1145450. PubMed ID: 37359524
[TBL] [Abstract][Full Text] [Related]
11. A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
Li H; Lv Z; Liu M
Medicine (Baltimore); 2023 Oct; 102(41):e35196. PubMed ID: 37832111
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.
Jiang Y; Ye Y; Huang Y; Wu Y; Wang G; Gui Z; Zhang M; Zhang M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15069-15083. PubMed ID: 37620430
[TBL] [Abstract][Full Text] [Related]
13. A novel molecular subtypes and risk model based on inflammatory response-related lncrnas for bladder cancer.
Tang F; Zhang J; Lu Z; Liao H; Hu C; Mai Y; Lai Y; Lu Z; Tang Z; Li Z; He Z
Hereditas; 2022 Aug; 159(1):32. PubMed ID: 35964079
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
16. A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
Jin Y; Li J; Tang C; He K; Shan D; Yan S; Deng G
Medicine (Baltimore); 2023 May; 102(18):e33664. PubMed ID: 37145007
[TBL] [Abstract][Full Text] [Related]
17. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
Hui P; Ni F; Zheng L; Jia L; Wang Z
BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
Wang H; Liu J; Tang R; Hu J; Liu M; Wang J; Zhang J; Hou H
Eur J Med Res; 2024 Jan; 29(1):52. PubMed ID: 38217031
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]